Abeona Therapeutics Inc. (LON:0H7R)

Market Cap	198.76M
Revenue (ttm)	n/a
Net Income (ttm)	-53.00M
Shares Out	n/a
EPS (ttm)	-1.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	858
Average Volume	1,379
Open	5.88
Previous Close	5.83
Day's Range	5.86 - 5.88
52-Week Range	2.35 - 8.80
Beta	1.43
RSI	54.28
Earnings Date	Mar 26, 2025

About Abeona Therapeutics

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AI...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• CEO: Vishwas Seshadri
• Employees: 84
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0H7R

Financial Performance

In 2023, Abeona Therapeutics's revenue was $3.50 million, an increase of 147.52% compared to the previous year's $1.41 million. Losses were -$54.19 million, 24.6% more than in 2022.

Financial numbers in USD